BW 02
Alternative Names: BW-02Latest Information Update: 04 Feb 2025
Price :
$50 *
At a glance
- Originator Argo Biopharma
- Developer Argo Biopharma; Novartis
- Class Cardiovascular therapies; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cardiovascular disorders
Most Recent Events
- 30 Jan 2025 Phase-I clinical trials in Cardiovascular disorders (Parenteral), before January 2025 (Argo Biopharma pipeline, January 2025)